MedTrace Logo

Interscalene Block and Dysfunction Diaphragmatic

NCT04173364 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-21

No results posted yet for this study

Summary

The study seeks to show that interscalene injection of a small volume (\<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.

Conditions

  • Diaphragmatic Paralysis

Interventions

DRUG

Ropivacaine 0.5% Injectable Solution

Injectable solution of ropivacaine 0.5%

DRUG

Ropivacaine 0.1% Injectable Solution

Dilution of ropivacaine to the concentration of 0.1%

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Arnaud ALLUIN, MD · University Hospital, Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2020-09-21
Completion
2020-09-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173364 on ClinicalTrials.gov